keyword
Keywords Metastatic hormone sensitive p...

Metastatic hormone sensitive prostate cancer

https://read.qxmd.com/read/38352133/double-trouble-unmasking-two-hook-effects-on-siemens-atellica%C3%A2-total-psa-and-total-hcg-assays
#21
Meryem Benamour, Pauline Brouwers, Arnaud Nevraumont, Tatiana Roy, Jean-Louis Bayart
The "hook effect" or "prozone phenomenon" occurs when the concentration of a particular analyte saturates the antibodies used in the test, resulting in falsely low or negative results despite the presence of high analyte concentrations. We report two recent cases of hook effect encountered with a widely used immunoassay analyzer, the Siemens Atellica® IM1600. The first case involves a patient with advanced metastatic prostate cancer whose total PSA (tPSA) concentration dropped dramatically from his last biological control...
March 2024: Practical Laboratory Medicine
https://read.qxmd.com/read/38347113/initial-management-approach-for-localized-locally-advanced-disease-is-critical-to-guide-metastatic-castration-resistant-prostate-cancer-care
#22
JOURNAL ARTICLE
Vincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, Giuseppina Bruno, Cristian Lolli, Giuseppe Schepisi, Aldo Rosano, Guido Giordano, Marianna Garofoli, Vincenzo Emanuele Chiuri, Lucia Fratino, Elisa Zanardi, Luca Galli, Francesco Massari, Ugo Falagario, Pasquale Rescigno, Giuseppe Fornarini, Francesca Sanguedolce, Daniele Santini, Giuseppe Procopio, Orazio Caffo, Giuseppe Carrieri, Matteo Landriscina, Ugo De Giorgi
BACKGROUND: Currently, several therapies are available for metastatic castration-resistant prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first sought the prognostic value of duration on androgen-deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) in patients receiving androgen-receptor-signaling inhibitors (ARSI) for mCRPC. METHODS: A multicenter cohort of mCRPC patients who started ARSI between July 2011 and October 2021 was identified...
February 12, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38327772/circulating-tumor-dna-and-tissue-complementarily-detect-genomic-alterations-in-metastatic-hormone-sensitive-prostate-cancer
#23
JOURNAL ARTICLE
Bin Yang, Tingting Zhao, Baijun Dong, Wei Chen, Guanjie Yang, Jun Xie, Changcheng Guo, Ruiliang Wang, Hong Wang, Longfei Huang, Bo Peng, Wei Xue, Xudong Yao
The clinical utility of circulating tumor DNA (ctDNA) in hormone-sensitive prostate cancer (HSPC) remains inadequately elucidated. This study presents the largest real-world cohort to conduct a concordance analysis between ctDNA and tissue-based genomic profiling in HSPC patients. The findings reveal diminished ctDNA abundance in cases with low tumor burden and demonstrate an increased concordance rate between ctDNA and tissue along with the progression of disease burden. Notably, a substantial number of exclusive genomic alterations (GAs) were identified either in ctDNA or tissue in high-volume metastatic disease...
February 16, 2024: IScience
https://read.qxmd.com/read/38323376/enzalutamide-and-leuprolide-acetate-in-non-metastatic-hormone-sensitive-prostate-cancer-the-sooner-the-better
#24
EDITORIAL
Emilio Francesco Giunta, Lorenzo Gasperoni, Ugo De Giorgi
No abstract text is available yet for this article.
February 2024: Future Oncology
https://read.qxmd.com/read/38320519/targeting-androgen-receptor-mutations-in-metastatic-castration-resistant-prostate-cancer-with-a-novel-androgen-biosynthesis-inhibitor
#25
EDITORIAL
Xin Gao
Multiple therapeutic advances in recent years have significantly improved outcomes for patients with metastatic prostate cancer, including utilization of combination androgen receptor (AR) pathway inhibitors and/or taxane chemotherapy in earlier, hormone-sensitive disease.1 Unfortunately, patients typically still develop metastatic castration-resistant prostate cancer (mCRPC), the lethal form of disease with limited prognosis. Despite castration resistance, the majority of patients with mCRPC continue to have AR-dependent disease through a variety of mechanisms, including emergence of AR mutations, amplifications, splice variants, and persistent AR activation via alternative pathways of androgen production...
January 2024: NEJM Evid
https://read.qxmd.com/read/38312049/evaluation-of-prostate-specific-membrane-antigen-expression-in-locally-advanced-or-metastatic-breast-carcinoma-with-68-ga-psma-11-positron-emission-tomography-computed-tomography-imaging-for-potential-theranostics
#26
JOURNAL ARTICLE
Rahul V Parghane, Tejal Suralkar, Dilip Nikam, Sandip Basu
BACKGROUND AND AIM: Prostate-specific membrane antigen (PSMA) is ubiquitously expressed in tumor-associated neovasculature and may be a potential theranostic in many solid cancers, including breast carcinoma (BC). Herein, we analyzed the presence of PSMA in BC, through qualitative and quantitative parameters on 68 Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT), across various hormonal subtypes. METHODS: This study examined 41 female patients of BC...
April 1, 2024: Nuclear Medicine Communications
https://read.qxmd.com/read/38311854/impact-of-presentation-timing-in-metastatic-hormone-sensitive-prostate-cancer-characterization-of-patients-and-identification-of-prognostic-factors
#27
JOURNAL ARTICLE
Juliana Arenas Hoyos, David Ruiz Londoño, Andres Gomez Hoyos, Estefania Celis Reyes, Rodolfo Varela, Julian Serrano Giraldo
BACKGROUND: The treatment and surveillance of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved since the introduction of several treatment intensification options associated with hormonal blockade and classifications based on the timing of metastatic disease presentation and disease volume. Using a hospital-based registry, we aimed to assess whether these new classifications are applicable to our population, as few studies have demonstrated their prognostic value for overall survival (OS) and time to development of castration-resistant prostate cancer (CRPC), and to establish prognostic factors in our population...
February 4, 2024: Prostate
https://read.qxmd.com/read/38291265/metastatic-hormone-sensitive-prostate-cancer-in-the-era-of-doublet-and-triplet-therapy
#28
REVIEW
Anthony V Serritella, Maha Hussain
Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy...
January 4, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38284349/pembrolizumab-for-metastatic-castration-resistant-prostate-cancer-trials-and-tribulations
#29
REVIEW
Alexander K Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S Antonarakis
INTRODUCTION: Immunotherapies have revolutionized the management of various malignancies but have only recently been evaluated systematically in prostate cancer. Pembrolizumab, a programmed-death 1 (PD-1) blocking antibody, has been utilized in a small subset of prostate cancer patients with mismatch repair deficiency/microsatellite instability, but has now been assessed in broader populations of metastatic prostate cancer patients. AREAS COVERED: The results of four pembrolizumab-based phase III clinical trials for metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) patients, including KEYNOTE-641, KEYNOTE-921, KEYNOTE-991, and KEYLYNK-010 are summarized...
2024: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/38272747/a-phase-2-randomized-open-label-study-of-oral-darolutamide-monotherapy-versus-androgen-deprivation-therapy-in-men-with-hormone-sensitive-prostate-cancer-eortc-gucg-1532
#30
JOURNAL ARTICLE
Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, Fernando López-Campos, Piet Ost, Thierry Andre Roumeguere, Bernardo Herrera-Imbroda, Lionel A D'Hondt, Magali Quivrin, Paolo Gontero, Salvador Villà, Hussein Khaled, Beatrice Fournier, Jammbe Musoro, Joanna Krzystyniak, Yassin Pretzenbacher, Yohann Loriot
BACKGROUND AND OBJECTIVE: Darolutamide is an androgen receptor inhibitor that increases overall survival in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer (PCa). This phase 2 study assessed the efficacy and safety of darolutamide as monotherapy without ADT in patients with eugonadal testosterone levels. METHODS: This was a 24-wk, open-label, randomized study of patients with hormone-sensitive, histologically confirmed PCa requiring gonadotropin-releasing hormone (GnRH); an Eastern Cooperative Oncology Group performance status score of 0/1; and life expectancy >1 yr...
January 24, 2024: European Urology Oncology
https://read.qxmd.com/read/38268482/an-objective-measure-of-response-on-whole-body-mri-in-metastatic-hormone-sensitive-prostate-cancer-treated-with-androgen-deprivation-therapy-external-beam-radiotherapy-and-radium-223
#31
JOURNAL ARTICLE
Valentina Giacometti, Arthur C Grey, Aaron J McCann, Kevin M Prise, Alan R Hounsell, Conor K McGarry, Joe M O'Sullivan
OBJECTIVES: The aim of this study was to generate an objective method to describe MRI data to assess response in the vertebrae of patients with metastatic hormone sensitive prostate cancer (mHSPC), treated with external beam radiation therapy and systemic therapy with Radium-223 and to correlate changes with clinical outcomes. METHODS: Three sets of whole-body MRI (WBMRI) images were utilized from 25 patients from the neo-adjuvant Androgen Deprivation Therapy pelvic Radiotherapy and RADium-223 (ADRRAD) clinical trial: MRI1 (up to 28 days before Radium-223), MRI2 and MRI3 (2 and 6 months post completion of Radium-223)...
January 24, 2024: British Journal of Radiology
https://read.qxmd.com/read/38267304/real-world-evidence-of-triplet-therapy-in-metastatic-hormone-sensitive-prostate-cancer-an-austrian-multicenter-study
#32
JOURNAL ARTICLE
Mona Kafka, Giulia Giannini, Nastasiia Artamonova, Hannes Neuwirt, Heidemarie Ofner, Gero Kramer, Thomas Bauernhofer, Ferdinand Luger, Thomas Höfner, Wolfgang Loidl, Hubert Griessner, Lukas Lusuardi, Antonia Bergmaier, Andreas Berger, Thomas Winder, Sarah Weiss, Severin Bauinger, Steffen Krause, Martin Drerup, Elmar Heinrich, Magdalena Schneider, Stephan Madersbacher, Sonia Vallet, Franz Stoiber, Sarah Laimer, Stephan Hruby, Gert Schachtner, Udo Nagele, Sebastian Lenart, Anton Ponholzer, Jacob Pfuner, Clemens Wiesinger, Christoph Kamhuber, Ecan Müldür, Jasmin Bektic, Wolfgang Horninger, Isabel Heidegger
INTRODUCTION: Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC). PATIENTS AND METHODS: We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical centers, among them 79.4% of patients received abiraterone and 17...
January 4, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38262848/effect-of-concomitant-medications-on-treatment-response-and-survival-in-de-novo-metastatic-prostate-cancer-secondary-analysis-of-the-latitude-study
#33
JOURNAL ARTICLE
Soumyajit Roy, Fred Saad, Christopher J D Wallis, Yilun Sun, Daniel E Spratt, Rishav Akilla, Amar U Kishan, Shawn Malone, Scott C Morgan
PURPOSE: It is unclear whether exposure to commonly prescribed medications influences survival and treatment response in patients with de novo high-risk metastatic prostate cancer (mPCa) treated with androgen receptor pathway inhibitors (ARPIs). METHODS: We performed a secondary analysis of the LATITUDE trial to determine whether receipt of concomitant medications influenced the effect of abiraterone acetate and prednisone, in addition to androgen deprivation therapy (ADT), on overall survival (OS) and prostate cancer-specific mortality (PCSM) in patients with de novo mPCa...
March 2024: European Journal of Cancer
https://read.qxmd.com/read/38251778/lower-pretreatment-serum-testosterone-level-predicts-poor-prognosis-in-the-patients-with-metastatic-hormone-sensitive-prostate-cancer-undergoing-androgen-deprivation-therapy
#34
JOURNAL ARTICLE
Takahiro Yoshida, Taketo Kawai, Kanade Hagiwara, Kazuki Yanagida, Michio Noda, Yuumi Tokura, Itsuki Yoshimura, Tomoyuki Kaneko, Tohru Nakagawa
OBJECTIVE: This study aimed to reveal the association between pretreatment serum testosterone levels and prognosis in patients with metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy. METHODS: A total of 91 patients were included in this retrospective study. Clinical data were obtained through chart review. Multivariate cox proportional hazards analyses addressed the impact of variables on castration-resistant prostate cancer-free and overall survivals...
January 20, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38232756/-palliative-urologic-surgery-for-metastatic-prostate-cancer-what-needs-to-be-considered-in-the-future
#35
JOURNAL ARTICLE
Axel Heidenreich, Christian Bach, David Pfister
Androgen deprivation in combination with novel hormonal agents, docetaxel or the combination of abiraterone/prednisone plus docetaxel or darolutamide plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favourable response rates, basically all patients will develop castration-resistant prostate cancer (CRPC) within 2...
January 17, 2024: Aktuelle Urologie
https://read.qxmd.com/read/38205078/development-of-parp-inhibitors-in-advanced-prostate-cancer
#36
REVIEW
Maria Teresa Bourlon, Paola Valdez, Elena Castro
The relatively high prevalence of alterations in the homologous recombination repair (HRR) pathway described in advanced prostate cancer provides a unique opportunity to develop therapeutic strategies that take advantage of the decreased tumor ability to repair DNA damage. Poly ADP-ribose polymerase (PARP) inhibitors have been demonstrated to improve the outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients with HRR defects, particularly in those with BRCA1/2 alterations. To expand the benefit of PARPi to patients without detectable HRR alterations, multiple studies are addressing potential synergies between PARP inhibition (PARPi) and androgen receptor pathway inhibitors (ARSi), radiation, radioligand therapy, chemotherapy, or immunotherapy, and these strategies are also being evaluated in the hormone-sensitive setting...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38201475/cell-free-dna-genomic-profiling-and-its-clinical-implementation-in-advanced-prostate-cancer
#37
JOURNAL ARTICLE
Ivana Bratic Hench, Luca Roma, Floriana Conticelli, Lenard Bubendorf, Byron Calgua, Clémentine Le Magnen, Salvatore Piscuoglio, Mark A Rubin, Alin Chirindel, Guillaume P Nicolas, Tatjana Vlajnic, Tobias Zellweger, Arnoud J Templeton, Frank Stenner, Christian Ruiz, Cyrill Rentsch, Lukas Bubendorf
Most men with prostate cancer (PCa), despite potentially curable localized disease at initial diagnosis, progress to metastatic disease. Despite numerous treatment options, choosing the optimal treatment for individual patients remains challenging. Biomarkers guiding treatment sequences in an advanced setting are lacking. To estimate the diagnostic potential of liquid biopsies in guiding personalized treatment of PCa, we evaluated the utility of a custom-targeted next-generation sequencing (NGS) panel based on the AmpliSeq HD Technology...
December 21, 2023: Cancers
https://read.qxmd.com/read/38198103/cost-effectiveness-analysis-of-systemic-therapy-for-intensification-of-treatment-in-metastatic-hormone-sensitive-prostate-cancer-in-india
#38
JOURNAL ARTICLE
Nidhi Gupta, Dharna Gupta, Kiran Gopal Vaska, Shankar Prinja
BACKGROUND AND OBJECTIVE: Androgen-deprivation therapy is the mainstay of treatment for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). However, the intensification of treatment with either docetaxel or novel anti-androgens (abiraterone-acetate plus prednisone [AAP], enzalutamide, and apalutamide) is being recommended based on the improved clinical outcomes and quality of life among patients. This study aimed to determine the most cost-effective drug for treatment intensification for patients with mHSPC in India...
January 10, 2024: Applied Health Economics and Health Policy
https://read.qxmd.com/read/38197234/-cost-effectiveness-analysis-and-budget-impact-analysis-of-enzalutamide-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer
#39
JOURNAL ARTICLE
Keiko Asakawa, Koki Idehara, Atsushi Saito, Takeshi Mitomi, Ataru Igarashi
We conducted cost-effectiveness analysis and budget impact analysis for androgen deprivation therapy (ADT) plus enzalutamide (ENZ) on patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the publicly-funded healthcare system perspective. Using a partitioned survival model, lifetime costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) of ADT+ENZ were estimated against ADT alone, ADT plus abiraterone (ADT+ABI), and ADT plus apalutamide (ADT+APA)...
December 2023: Hinyokika Kiyo. Acta Urologica Japonica
https://read.qxmd.com/read/38191022/evaluating-policies-of-expanding-versus-restricting-first-line-treatment-choices-a-cost-effectiveness-analysis-framework
#40
JOURNAL ARTICLE
Boshen Jiao, Josh J Carlson, Louis P Garrison, Anirban Basu
OBJECTIVES: Healthcare payers often implement coverage policies that restrict the utilization of costly new first-line treatments. Cost-effectiveness analysis can be conducted to inform these decisions by comparing the new treatment with an existing one. However, this approach may overlook important factors such as treatment effect heterogeneity and endogenous treatment selection, policy implementation costs, and diverse patient preferences across multiple treatment options. We aimed to develop a cost-effectiveness analysis framework that considers these real-world factors, facilitating the evaluation of alternative policies related to expanding or restricting first-line treatment choices...
January 6, 2024: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
161291
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.